Treatment of PD-L1-negative melanoma using an anti-PD-1 antibody and an anti-CTLA-4 antibody
AssigneeBristol-Myers Squibb Company
InventorArvin Yang
Life of this patent
Estimating the term…
Abstract
The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1-negative melanoma and (ii) administering to the patient a combination of an anti-PD-1 antibody or an antigen-binding portion thereof and an anti-CTLA-4 antibody or an antigen-binding portion thereof. The methods of the invention can extend progression-free survival for over 8 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.
Claims11
A method for treating a melanoma tumor in a patient in need thereof comprising administering to the patient:
- (a) about 1 mg/kg nivolumab and 3 mg/kg ipilimumab every three weeks for about 4 doses;
- followed by
- (b) a dose of nivolumab, wherein the dose is a flat dose of about 240 mg or about 480 mg.
Dependencies are inferred from the claim text.